Literature DB >> 2495286

High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3.

A Walsh1, Y Ito, J L Breslow.   

Abstract

Five lines of transgenic mice, which had integrated the human apolipoprotein (apo) A-I gene and various amounts of flanking sequences, were established. Normally, apoA-I is expressed mainly in liver and intestine, but all of the transgenic lines only expressed apoA-I mRNA in liver, strongly suggesting that 256 base pairs of 5'-flanking sequence was sufficient for liver apoA-I gene expression but that 5.5 kilobase pairs was not sufficient for intestinal expression. Mean plasma levels of human apoA-I varied in different lines from approximately 0.1 to 200% of normal mouse levels. This was not dependent on the amount of flanking sequence. Lipoprotein levels were studied in detail in one of the lines with a significantly increased apoA-I pool size. In one study, the total plasma apoA-I level (mouse plus human) was 381 +/- 43 mg/dl in six animals from this line, compared to 153 +/- 17 mg/dl in matched controls. Total and high density lipoprotein cholesterol (HDL-C) levels were increased 60% in transgenic animals, compared to controls (total cholesterol: 125 +/- 12 versus 78 +/- 13 mg/dl, p = 0.0001; HDL-C 90 +/- 7 versus 55 +/- 11 mg/dl, p = 0.0001). The molar ratio of HDL-C/apoA-I was significantly lower in transgenic animals, 17 +/- 1 versus 25 +/- 2 (p = 0.0001), suggesting the increase was in smaller HDL particles. This was confirmed by native gradient gel electrophoresis. This was not due to aberrant metabolism of human apoA-I in the mouse, since human apoA-I was distributed throughout the HDL particle size range and was catabolized at the same rate as mouse apoA-I. In another study of 23 transgenic mice, HDL-C and human apoA-I levels were highly correlated (r = 0.87, p less than 0.001). The slope of the correlation line also indicated the additional HDL particles were in the smaller size range. We conclude that human apoA-I can be incorporated into mouse HDL, and excessive amounts increase HDL-C levels primarily by increasing smaller HDL particles, comparable to human HDL3 (HDL-C/apoA-I molar ratio = 18).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495286

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels.

Authors:  T Hayek; T Chajek-Shaul; A Walsh; L B Agellon; P Moulin; A R Tall; J L Breslow
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Plasma carboxyl ester lipase activity modulates apolipoprotein B-containing lipoprotein metabolism in a transgenic mouse model.

Authors:  Ling Li; Wei Weng; Earl H Harrison; Edward A Fisher
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

Review 4.  Transcription factors as drug targets: opportunities for therapeutic selectivity.

Authors:  T R Butt; S K Karathanasis
Journal:  Gene Expr       Date:  1995

5.  Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.

Authors:  P Holvoet; S Danloy; E Deridder; M Lox; H Bernar; A Dhoest; D Collen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

6.  Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia.

Authors:  M Merkel; P H Weinstock; T Chajek-Shaul; H Radner; B Yin; J L Breslow; I J Goldberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice.

Authors:  L Masucci-Magoulas; P Moulin; X C Jiang; H Richardson; A Walsh; J L Breslow; A Tall
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4.

Authors:  G S Ginsburg; J Ozer; S K Karathanasis
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells.

Authors:  R L Widom; J A Ladias; S Kouidou; S K Karathanasis
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

10.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.